TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

VIEKIRA PAK (COPACKAGED)

DASABUVIR SODIUM
Approved 2014-12-19
2
Indications
--
Phase 3 Trials
2
Priority Reviews
11
Years on Market

Details

Status
Discontinued
First Approved
2014-12-19
Routes
ORAL
Dosage Forms
TABLET

VIEKIRA PAK (COPACKAGED) Approval History

Loading approval history...

What VIEKIRA PAK (COPACKAGED) Treats

2 FDA approvals

Originally approved for its first indication in 2014 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

VIEKIRA PAK (COPACKAGED) FDA Label Details

Pro

VIEKIRA PAK (COPACKAGED) Patents & Exclusivity

Latest Patent: Oct 2033

Patents (15 active)

US9629841 Expires Oct 18, 2033
US10201542 Expires Oct 18, 2033
US8466159 Expires Sep 4, 2032
US8680106 Expires Sep 4, 2032
US8685984 Expires Sep 4, 2032
US8492386 Expires Sep 4, 2032
US8691938 Expires Apr 13, 2032
US8686026 Expires Jun 9, 2031
US9044480 Expires Apr 10, 2031
US8420596 Expires Apr 10, 2031
+ 5 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.